A comparative meta-analysis of the efficacy and tolerability of pregabalin versus placebo for the management of fibromyalgia in adults

Ryan Davies

Abstract


Background

Fibromyalgia (FM) is a multifactorial condition of unknown aetiology. Although it is primarily characterised by chronic diffuse pain, it is also associated with a number of symptoms including: cognitive impairment, sleep problems, fatigue, anxiety and depression. FM patients frequently report of a reduced quality of life, and this often due to the inherent disability associated with these symptoms. Although there is currently no curative treatment for FM, the anti-convulsant drug pregabalin is one of a number of interventions employed to manage this condition.

Objectives

To assess the efficacy and tolerability of pregabalin for the management of FM in adults compared to a placebo.  

Search methods

Electronic searches were performed using the Cochrane Central Register of

Controlled Trials (CENTRAL) (Issue 1, 2017), MEDLINE accessed through PubMed

(1966 to December 2016), and www.clinicaltrials.gov(website of the US National Institute of Health) to December 2016 for unpublished clinical trials. Additionally, searches were performed on the bibliographies of existing reviews to retrieve relevant articles. 

Selection criteria

The studies included in this review investigated the efficacy and tolerability of pregabalin for the management of FM in adults. They were all full journal publications of randomised controlled trials (RCTs) which employed a double-blind experimental procedure and lasted for eight weeks or longer.

 

Data collection and analysis

The titles and abstracts of studies were individually scrutinised to determine their eligibility for inclusion. Studies which obviously did not satisfy the basic inclusion criteria (i.e. double-blind, RCT) were excluded outright. Full copies of potential studies were obtained and read in-depth to ascertain their eligibility for inclusion.  The risk of bias was determined for each study using the criteria described in the

Cochrane Handbook for Systematic Reviews of Interventions [Higgins and Green

2011]. Data was then extracted and double-checked for accuracy prior to entry into

Review Manager 5 [RevMan, 2014] 

Main results

This review includes eight studies of both classical and enriched enrolment randomised withdrawal (EERW) design.   Six studies of classical design (3812 participants) were included in this review.  Participants were randomised at the start of the study to receive either: 150, 300, 450 or 600 mg daily pregabalin or placebo for 8 to 13 weeks. All studies used a placebo as the comparator. The studies had a low risk of bias with the exception of the last observation carried forward (LOCF) imputation for missing data which can overestimate or underestimate the magnitude of treatment effect.  With regards to pain outcomes, pregabalin was more effective than placebo in reducing mean pain scores (SMD: -0.26; 95% CI; -0.34 to -0.19; P = <0.00001), as well as achieving both ≥30% (RR: 1.38; 95% CI; 1.23 to 1.55; P = 0.00001) and ≥50% reductions in pain intensity (RR: 1.61; 95% CI; 1.35 to 1.93; P = 0.00001); the numbers needed to treat for an additional beneficial (NNTB) outcome by pregabalin over placebo was ≈9 and ≈12 respectively. The overall effect of pregabalin in producing improvements to patient global impression of change (PGIC) was statistically significant (RR: 1.40; 95% CI; 1.25 to 1.58; P = 0.00001); the NNTB by pregabalin over placebo was ≈9. Pregabalin did not substantially reduce fatigue (SMD: -0.17; 95% CI; -0.25 to -0.09; P = <0.0001), anxiety (SMD: -0.13; 95% CI; -0.21 to -0.06; P = <0.0007), depression (SMD: -0.10; 95% CI; -0.18 to -0.02; P=0.01) or health related quality of life (SMD: 0.17; 95% CI; -0.26 to -0.09; P = <0.0001), but produced modest improvements to symptoms of sleep problems (SMD: -0.34; 95% CI; -0.42 to -0.27; P = <0.0001). The incidence of participant withdrawal was higher with pregabalin than placebo (RR: 1.75; 95% CI; 1.42 to 2.15; P = 0.00001); the numbers needed for an additional harmful outcome (NNTH) by pregabalin over placebo was ≈12.  Somnolence and dizziness are two of the most common side-effect of pregabalin; both occurred more frequently following treatment with pregabalin as opposed to placebo; (RR: 3.89; 95% CI; 3.16 to 4.78; P = 0.00001) for dizziness and (RR: 3.42; 95% CI; 2.71 to 4.32; P = 0.00001) for somnolence. The NNTH by pregabalin over placebo was ≈3 for dizziness, and ≈7 for somnolence respectively.  With regards to the incidence of serious adverse effects, there was no significant difference between pregabalin and placebo (RR: 1.06; 95% CI; 0.73 to 1.53; P = 0.31). Two studies (687 participants) of EERW design were included in this review. They were deemed as having a low risk of bias as there was no missing data and no imputation. The maintenance of therapeutic effect (MTR) was used as the primary efficacy outcome in this review. Of the participants whom entered the double-blind treatment phase, 39.8% of participants receiving pregabalin, and 20.9% of participants receiving placebo achieved MTR. The overall effect of pregabalin on achieving MTR was statistically significant (RR: 1.9; 95% CI; 1.5 to 2.4; P = 0.00001) and the NNTB by pregabalin over placebo was ≈5. As with the studies of classical design, the incidence of adverse effects was higher with pregabalin than placebo. 64.9% of participants experienced at least one adverse effect following treatment with pregabalin, as opposed to 48.7% of those receiving placebo. The overall effect of pregabalin in causing adverse effects was statistically significant (RR: 1.3; 95% CI; 1.2 to 1.5; P = 0.000028), and the NNTH by pregabalin over placebo was ≈6. 

 

Author’s conclusions

Pregabalin 300 to 600 mg daily has the potential to achieve substantial improvements the symptoms of FM, but this is generally observed in a minority of participants. Although its use can yield small improvements to the symptoms of pain and sleep problems, it is generally less effective in addressing the other symptoms of FM (i.e. fatigue, anxiety). Although the use of pregabalin is not associated with any serious adverse effects, participants typically experience adverse effects (i.e. somnolence and dizziness) more frequently than in the placebo group.  Furthermore, the incidence of participant withdrawal due to adverse effects was higher in the pregabalin group. Generally speaking these observations did not follow a dose response relationship.  


Full Text:

PDF

References


References to studies included in this review

Arnold, LM., Russell, IJ., Diri, EW., Duan, WR., Young, JP., Sharma, U., Martin, SA., Barrett, JA., and Haig, G. [2008] A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. Pain; 9(9):792-805. [DOI: 10.1016/j.jpain.2008.03.013]

Arnold, LM., Arsenault, P., Huffman, C., Patrick, JL., Messig, M., Chew, ML., Sanin, L., Scavone, JM., Pauer, L., and Clair, AG. [2014] Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo controlled study. Current Medical Research and Opinion; 30(10):2069-2083. [DOI:

1185/03007995.2014.928275]

Crofford, LJ., Rowbotham, MC., Mease, PJ., Russell, IJ., Dworkin, RH., Pregabalin 1008105 Study Group, et al. [2005] Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism; 52(4):1264-73. [DOI: 10.1002/art.20983]

Crofford, LJ., Mease, PJ., Simpson, SL., Young, JP., Martin, SA., Haig, GM., et al. [2008] Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain; 136(3):419-31. [DOI: 10.1016/j.pain.2008.02.027]

Mease, PJ., Russell, IJ., Arnold, LM., Florian, H., Young, JP., Martin, SA., et al. [2008]

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. Journal of Rheumatology; 35 (3):502-14. [PMID: 18278830]

Nasser, K., Kivitz, AJ., Maricic, MJ., Silver, DS., Silverman, SL. [2014] Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care and Research; 66(2):293-300. [DOI:

1002/acr.22111]

Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., Nishioka, K. [2012] A randomized, doubleblind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Research and Therapy; 14(5):217. [DOI: 10.1186/ar4056]

Pauer, L., Winkelmann, A., Arsenault, P., Jespersen, A., Whelan, L., Atkinson, G. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. Journal of Rheumatology; 38(12):2643-52. [DOI: 10.3899/jrheum.110569]

References to studies excluded from this review

Arnold, LM., Crofford, LJ., Martin, SA., Young, JP., Sharma, U. [2007] The Effect of Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial of Pregabalin for Treatment of Fibromyalgia. Pain Medicine; 8(8):633-638. [DOI:10.1111/j.15264637.2007.00332.x]

Arnold, LM., Emir, B., Murphy, KT., Zeiher, BG., Pauer, L., Scott, G., Petersel, D. [2012] Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics; 34(5):1092-1102. [DOI: doi: 10.1016/j.clinthera.2012.03.003]

Arnold, L., Sarzi-Puttini, P., Arsenault, P., Khan, TS., Brown, PB., Clair, A., Driscoll, J., Landen, J., Pauer, L. [2014b] Pregabalin improves fibromyalgia symptoms in patients with fibromyalgia and comorbid depression receiving antidepressant medication: results from a randomized, 2-way crossover, double-blind, placebo-controlled study. Pain; 15(4):74. [DOI: 10.1016/j.jpain.2014.01.306]

Arnold, L., Sarzi-Puttini, P., Asenault, P., Khan, T., Brown, PB., Clair, A., Driscoll, J., Landen, J., Pauer, L. [2014c] Pregabalin is effective irrespective of antidepressant class in fibromyalgia patients currently receiving antidepressant medication for comorbid depression. Pain; 15(4):75. [DOI: http://dx.doi.org/10.1016/j.jpain.2014.01.307]

Arnold, LM., Sarzi-Puttini, P., Arsenault, P., Khan, T., Bhadra-Brown, P., Clair, A. [2015] Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study. Journal of Rheumatology; 42(7):1237-44. [DOI: 10.3899/jrheum.141196]

Arnold, LM., Schikler, KN., Bateman, L., Khan, T., Pauer, L., Bhadra-Brown, P., Clair, A., Chew, ML., Scavone, J. [2016] Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatric Rheumatology; 14(46). [DOI: 10.1186/s12969-016-0106-4]

Byon, W., Ouellet, D., Chew, M., Ito, K., Burger, P., Pauer, L. [2010] Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change. Journal of Clinical Pharmacology; 50(7):803-15. [DOI:

1177/0091270009352187]

Emir, B., Murphy, TK., Petersel, DL., Whalen, E. [2010] Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opinion on

Pharmacotherapy; 11(14):2275-80. [DOI: 10.1517/14656566.2010.509717]

Häuser, W., Bernardy, K., Uçeyler, N., Sommer, C. [2009] Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain; 145(1):69-81. [DOI: 10.1016/j.pain.2009.05.014]

Moore, RA., Straube, S., Wiffen, PG., Derry, S., McQuay HJ. [2009] Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews; 8(3). [DOI:

1002/14651858.CD007076.pub2]

Pfizer (NCT00760474) [2012]. A double-blind, placebo-controlled cross-over study in fibromyalgia subjects to examine effects of pregabalin on brain response to mechanical pain as assessed by functional magnetic resonance imaging, proton magnetic resonance spectroscopy and subjective ratings. [Other: clinicaltrials.gov/ct2/show/NCT00760474]

Pfizer (NCT01268631) [2010]. Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile? [Other: clinicaltrials.gov/ct2/show/NCT01268631]

Pfizer (NCT01904097) [2013]. Study of the brain with optic functional neuroimaging in patients with chronic pain using transcranial direct current stimulation. [Other: clinicaltrials.gov/ct2/show/NCT01904097]

Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., Nishioka, K. [2013] An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology; 23(6):1108-15. [DOI:

1007/s10165-012-0803-x]

Ramzy, EA. [2016] Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Practice; 17(1); 32-40. [DOI: 10.1111/papr.12409]

Roth, T., Lankford, DA., Bhadra, P., Whalen, E., Resnick, EM. [2012] Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo controlled, 2-way crossover polysomnography study. Arthritis Care and Research; 64(4):597-606. [DOI: 10.1002/acr.21595]

Russell, IJ., Crofford, LJ., Leon, T., Cappelleri, JC., Bushmakin, AG., Whalen, E. [2009] The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine; 10(6): 604-10. [DOI: 10.1016/j.sleep.2009.01.009]

References to ongoing studies

NCT02146430 [2012]. A randomized, double-blind, placebo- and active-controlled study of DS5565 for treatment of pain associated with fibromyalgia.

clinicaltrials.gov/ct2/show/NCT02146430 (accessed 23 November 2016). [4388205; Sponsor ID: DS5565-A-E309]

Additional references

Arnold, LM., Emir, B., Murphy, TK., Zeiher, BG., Pauer, L., Scott, G., and Petersel, D. [2012] Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics; 34(5); 1092-1102. [DOI: http://dx.doi.org/10.1016/j.clinthera.2012.03.003]

Bellato, E., Marini, Eleonora., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, DE., and Blonnda, D. [2012] Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis and Treatment. Pain Research and Treatment. [DOI: 10.1155/2012/426130]

Bennett, R., Jones, J., Turk, D., Russell, I. and Matallana, L. [2007] An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders; 8(2). [DOI: 10.1186/14712474-8-27]

Bhusal, S., Diomampo, S., and Magrey, MN. [2016] Clinical utility, safety and efficacy of pregabalin in the treatment of fibromyalgia. Drug Healthcare and Patient Safety; 8; 13-23. [DOI:

2147/DHPS.S95535]

Branco, JC., Bannwarth, B., Failde, I., Abello Carbonell, J., Blotman, F., Spaeth, M., Saraiva, F., Nacci, F., Thomas, E., Caubère, JP., Le Lay, K., Taieb, C., and Matucci-Cerinic M. [2010]

Prevalence of Fibromyalgia: a survey in five European countries. Seminars in Arthritis and Rheumatism; 39(6); 448-453. [DOI: 10.1016/j.semarthrit.2008.12.003]

Clauw, D. [2014] Fibromyalgia: a clinical review. JAMA; 311(15), 1547-1555. [DOI

1001/jama.2014.3266]

Cohen, J. (2013). Statistical Power Analysis for the Behavioral Sciences. 1st ed. Hoboken: Taylor and Francis.

Cook, R. and Sackett, D. [1995] The number needed to treat: a clinically useful measure of treatment effect. BMJ, 310(6977), pp.452-454.

Dechartres, A., Trinquart, L., Boutron, I. and Ravaud, P. [2013] Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ; 346f2304. [DOI: https://doi.org/10.1136/bmj.f2304]

Derry, S., Cording, M., Wiffen, PJ., Law, S., Phillips, T., and Moore, RA. [2016] Pregabalin for pain in fibromyalgia adults. Cochrane Database of Systematic Reviews; 9; [DOI: 10.1002/14651858.CD011790.pub2]

Dworkinl, RH., Turk, DC., Wyrwich, KW., Beaton, D., Cleeland, CS., Farrar, JT.,

Haythornthwaite, JA., Jensen, MP., Kerns, RD., Ader, DN., Brandenburg, N., Burke, LB., Cella, D., Chandler, J., Cowan, P., Dimitrova, R., Dionne, R., Hertz, S., Jadad, AR., Katz, NP., Kehlet, H., Kramer, LD., Manning, DC., McCormick, C., McDermott, MP., McQuay, HJ., Patel, S., Porter, L., Quessy, S., Rappaport, BA., Rauschkolb, C., Revicki, DA., Rothman, M., Schmader, KE., Stacey, BR., Stauffer, JW., von Stein, T., White, RE., Witter, J., Zavisic, S. [2008] Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Pain; 9(2); 105-121. [DOI: 10.1016/j.jpain.2007.09.005]

Gahr, M., Freudenmann, R., Hiemke, C., Kölle, M. and Schönfeldt-Lecuona, C. [2013] Pregabalin abuse and dependence in Germany: results from a database query. European Journal of Clinical Pharmacology; 69(6), 1335-1342. [DOI: 10.1007/s00228-012-1464-6]

Häuser, W., Henningsen, F. [2014] Fibromyalgia syndrome: a somatoform disorder? European Journal of Pain; 18(8), 1052-1059. [DOI: 10.1002/j.1532-2149.2014.00453.x]

Häuser, W., Ablin, J., Fizcharles, MA., Littlejohn, G., Usui, C. and Walitt, B. [2015] Fibromyalgia. Nature Reviews: Disease Primers; 1; 15022. [DOI: 10.1038/nrdp.2015.22]

Higgins, JPT., Thompson, SG., Deeks, JJ., Altman, DG. [2003] Measuring Inconsistency in metaanalyses. BMJ; 327(7414); 557-560. [DOI:10.1136/bmj.327.7414.557]

Jadad, AR., Moore, RA., Carroll, D., Jenkinson, C., Reynolds, DJ., Gavaghan, DJ., and McQuay, HJ. [1996] Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials; 17(1); 1-12. [PMID: 8721797]

Jahan, F., Nanji, K., Qidwai, W., and Quasim, R. [2012] Fibromyalgia Syndrome: An Overview of Pathophysiology, Diagnosis and Management. Oman Medical Journal; 27(3); 192-195. [DOI: 10.5001/omj.2012.44]

Kashikar-Zuck, S., Cunningham, N., Soumitri., S., Bromberg, MH., Lynch-Jordan, AM.,

Strotman, D., Peugh, J., Noll, J., Ting, TV., Powers, SW., Lovell, DJ., and Arnold, LM. [2014] LongTerm Outcomes of Adolescents With Juvenile-Onset Fibromyalgia in Early Adulthood. Pediatrics; 133(3); 592-600. [DOI: 10.1542/peds.2013-2220].

Koroschetz, J., Rehm, SE., Gockel, U., Brosz, M., Freynhagen, R., Tölle, TR., and Baron, R. [2011] Fibromyalgia and neuropathic pain – differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology; 11(55). [DOI: 10.1186/1471-2377-11-55]

Lange, M., Petermann, F. [2010] influence of depression of fibromyalgia: a systematic review. Pain; 24:326-33. [DOI: 10.1007/s00482-010-0937-8]

Leresche, L. [2011] Defining gender disparities in pain management. Clinical Orthopaedics and Related Research; 469(7); 1871-1877. [DOI: 10.1007/s11999-010-1759-9]

Lunn, MP., Hughes, RA., and Wiffen, PJ. [2014] Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews; (1): CD007115. [DOI: 10.1002/14651858.CD007115.pub3]

Mease, P., Arnold, LM., Choy, EH., Clauw, DJ., Crofford, L., Glass, JM., Martin, SA., Morea, J., Simon, L., Strand, V., and Williams, DA. [2009] Fibromyalgia Syndrome Module at OMERACT 9. Journal of Rheumatology; 36(10); 2318-2329. [DOI: 10.3899/jrheum.090367]

Moore, RA., Straube, S., Paine, J., Phillips, CJ., Derry, S., and McQuay, HJ. [2010] Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain; 149(2); 360-364. [DOI:

1016/j.pain.2010.02.039]

Moore, RA., Eccleston, C., Derry, S., Wifen, P., Bell, RF, Straube, S., McQuay, H., [2010b]

ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in

Pain Relief; Cochrane Pain and Palliative and Supportive Care Systematic Review Group Editors. Pain; 150(3); 386-389. [DOI: 10.1016/j.pain.2010.05.011]

Moore, A., Derry, S., Eccleston, C., and Kalso, E. [2013] Expect analgesic failure; pursue analgesic success. BMJ; 346:f2690. [DOI: 10.1136/bmj.f2690]

Moore, RA., Derry, S., Aldington, D., Cole, P., Wiffen, PJ. [2015] Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews; (7): CD008242. [DOI:

1002/14651858.CD008242.pub3]

O’Brien, EM., Staud, RM., Hassinger, AD., McCulloch, RC., Craggs, JG., Atchison, JW., Price, DD., and Robinson, ME. [2010] Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine; 11(1); 6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]

Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., and Nishioka, K. [2013] An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology/the Japan Rheumatism Association; 23(6):1108-15. [DOI: 10.1007/s10165-012-0803-x]

Okifuki, A., and Hare, BD. [2013] Management of Fibromyalgia Syndrome: Review of Evidence. Pain and Therapy; 2(2); 87-104. [DOI: 10.1007/s40122-013-0016-9]

Queiroz, LP. [2013] Worldwide Epidemiology of Fibromyalgia. Current Pain and Headache Reports; 17(8); 356. [DOI: 10.1007/s11916-013-0356-5]

Rahman, A., [2014] Underwood, M. and Carnes, D. Fibromyalgia. BMJ; 24(348), 1224. [DOI:

1136/bmj.g1224].

Review Manager (RevMan) [2014] [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.

Ross, RL., Jones, KD., Bennett, RM., Ward, RL., Druker, BJ., and Wood, LJ. [2010] Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. The Open Immunology Journal; 3; 9-18. [PMID: 20467575]

Sawilowsky, SS. [2009] New effect size rules of thumb. Journal of Modern Applied Statistical Methods; 8(2), 597-599.

Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. [2012] Etiology and pathophysiology of fibromyalgia syndrome. Pain; 26:259-67. [DOI: 10.1007/s00482012-1174Straube, S., Derry, S., Moore, RA., and McQuay HJ. [2010] Pregabalin in fibromyalgia: metaanalysis of efficacy and safety from company clinical trial reports. Rheumatology; 49(4); 706-715. DOI: 10.1093/rheumatology/kep432

Taylor, CP., Angelotti, T., and Fauman, E. [2007] Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research; 73(2); 137-150. [DOI:

1016/j.eplepsyres.2006.09.008]

Toth, C. [2014] Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Therapeutic Advances in Drug Safety; 5(1); 38-56. [DOI:

1177/2042098613505614]

Tzellos, TG., Toulis, KA., Goulis, DG., Papazisis, G., Zampeli, VA., Vakfari, A., and Kouvelas, D. [2010] Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics; 35(6); 639-656. [DOI: 10.1111/j.1365-2710.2009.01144.x]

Üçeyler, N., Sommer, C., Walitt, B., Häuser W. [2013] Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews; (10):CD010782. [DOI:

1002/14651858.CD010782]

Vincent, A., Lahr, BD., Wolfe, F., Clauw, DJ., Whipple, MO., Oh, TH., Barton, DL., and St

Sauver, J. [2013] Prevalence of fibromyalgia: a population-based study in Olmsted County,

Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care and Research; 65(5); 786-792. [DOI: doi: 10.1002/acr.21896]

Wallace, DJ., Gavin, IM., Karpenko, O., Barkhordar, F., and Gillis, BS. [2015] Cytokine and chemokine profiles in fibromyalgia rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis. Rheumatology International; 35(6); 991-996. [DOI: 10.1007/s00296-014-3172-2]

Wiffen, PJ., Derry, S., Moore, RA., Aldington, D., Cole, P., Rice, A., Lunn, M., Hamunen, K., Haanpaa, M., and Kalso, EA. [2013] Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database of Systematic Reviews; (11):CD010567. [DOI: 10.1002/14651858.CD010567.pub2]

Wolfe, F., Smythe, HA., Yunus, MB., Bennett, RM., Bombardier, C., Goldenberg, DL.,

Tugwell, P., Campbell, SM., Ableles, M. and Clark, P. [1990] The American College of

Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism; 33(2); 160-162. PMID: 2306288

Wolfe, F., Clauw, DJ., Fitzcharles, MA., Goldenberg, DL., Katz, RS., Mease, P., Russell, AS., Russell, IJ., Winfield, JB., and Yunus, MB. [2010] The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research; 62(5); 600-110. [DOI: 10.1002/acr.20140.]

Wolfe, F., Clauw, DJ., Fitzcharles, MA., Goldenberg, DL., Häuser, W., Mease, P., Russell, AS., Russell, IJ., and Winfield, JB. [2011] Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. The Journal of Rheumatology; 38(6); 1113-1122. [DOI:

3899/jrheum.100594]

Wolfe, F., Brähler, E., Hinz, A., and Häuser, W. [2013] Fibromyalgia prevalence, somatic symptom reporting, and the Dimensionality of Polysymptomatic distress: Results from a survey of the general population. Arthritis Care & Research; 65(5), 777-785. [DOI:

1002/acr.21931]

Woolf, CJ. [2011] Central sensitization: implications for the diagnosis and treatment of pain. Pain; 152(3); 2-15. [DOI: 10.1016/j.pain.2010.09.030]

Yunus, MB. [2008] Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping condition, and the related issue of disease versus illness.

Seminars in Arthritis and Rheumatology; 37(6), 339-352. [DOI:

1016/j.semarthrit.2007.09.003]


Refbacks

  • There are currently no refbacks.


Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License

ISSN 1754-2383 [Online] ©University of Plymouth